Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

MRD in ALL: Optimization and Innovations

MRD in ALL: Optimization and Innovations Purpose of ReviewMeasurable residual disease (MRD) is an important monitoring parameter that can help predict survival outcomes in acute lymphoblastic leukemia (ALL). Identifying patients with MRD has the potential to decrease the risk of relapse with the initiation of early salvage therapy and to help guide decision making regarding allogeneic hematopoietic cell transplantation. In this review, we discuss MRD in ALL, focusing on advantages and limitations between MRD testing techniques and how to monitor MRD in specific patient populations.Recent FindingsMRD has traditionally been measured through bone marrow samples, but more data for evaluation of MRD via peripheral blood is emerging. Current and developmental testing strategies for MRD include multiparametric flow cytometry (MFC), next-generation sequencing (NGS), quantitative polymerase chain reaction (qPCR), and ClonoSeq. Novel therapies are incorporating MRD as an outcome measure to demonstrate efficacy, including blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor T (CAR-T) cell therapy.SummaryUnderstanding how to incorporate MRD testing into the management of ALL could improve patient outcomes and predict efficacy of new therapy options. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hematologic Malignancy Reports Springer Journals

MRD in ALL: Optimization and Innovations

Download PDF
13 pages

Loading next page...
 
/lp/springer-journals/mrd-in-all-optimization-and-innovations-YyVTDo2dZe

References (110)

Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022
ISSN
1558-8211
eISSN
1558-822X
DOI
10.1007/s11899-022-00664-6
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewMeasurable residual disease (MRD) is an important monitoring parameter that can help predict survival outcomes in acute lymphoblastic leukemia (ALL). Identifying patients with MRD has the potential to decrease the risk of relapse with the initiation of early salvage therapy and to help guide decision making regarding allogeneic hematopoietic cell transplantation. In this review, we discuss MRD in ALL, focusing on advantages and limitations between MRD testing techniques and how to monitor MRD in specific patient populations.Recent FindingsMRD has traditionally been measured through bone marrow samples, but more data for evaluation of MRD via peripheral blood is emerging. Current and developmental testing strategies for MRD include multiparametric flow cytometry (MFC), next-generation sequencing (NGS), quantitative polymerase chain reaction (qPCR), and ClonoSeq. Novel therapies are incorporating MRD as an outcome measure to demonstrate efficacy, including blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor T (CAR-T) cell therapy.SummaryUnderstanding how to incorporate MRD testing into the management of ALL could improve patient outcomes and predict efficacy of new therapy options.

Journal

Current Hematologic Malignancy Reports – Springer Journals

Published: Aug 1, 2022

Keywords: Acute lymphoblastic leukemia; Measurable residual disease

There are no references for this article.